缩宫素(Oxytocin) - 药物靶点：OXTR_在研适应症：宫缩乏力，子宫出血，流产_专利_临床

概要

基本信息

简介催产素是一种以商品名OXYTOCIN®销售的OXTR激动剂，是一种因其在妇产科领域的临床疗效而受到称赞的药物。催产素由诺华公司制造，诺华是一家在药物创新方面享有盛誉的制药公司，它于1980年首次在美国获得批准。该药物主要用于产前和产后护理，因为它已被证明可以有效诱导或加强子宫收缩。它的重组激素性质使其成为全球妇产科医生的首选药物，他们为需要产前和产后护理的女性寻求可靠和值得信赖的选择。此外，已发现催产素是孕妇常用的处方药，可帮助她们分娩和分娩或控制产后出血。

药物类型

合成多肽

别名

Oxytocin (JP17/USP/INN)、Oxytocin Nasal Spray、催产素

+ [14]

靶点

OXTR

作用方式

激动剂

作用机制

OXTR激动剂(催产素受体激动剂)

治疗领域

泌尿生殖系统疾病其他疾病神经系统疾病+ [2]

在研适应症

宫缩乏力子宫出血流产+ [11]

非在研适应症

萎缩性阴道炎萎缩注意缺陷障碍伴多动+ [7]

原研机构

Par Sterile Products LLC

在研机构

Tonix Pharmaceuticals Holding Corp.Viatris Pty Ltd.

ASKA Pharmaceutical Co., Ltd.

+ [3]

非在研机构

Peptonic Medical AB

GSK PlcThe General Hospital Corp.

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (1980-11-19),

流产出血催产+ [1]

最高研发阶段(中国)批准上市

特殊审评罕见儿科疾病 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C43H66N12O12S2

InChIKeyXNOPRXBHLZRZKH-DSZYJQQASA-N

CAS号50-56-6

Sequence Code 124252

来源: *****

关联

851

项与缩宫素相关的临床试验

NCT06364228

/ Not yet recruiting临床2期IIT

Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia

The overall aim of this study is to determine the efficacy and safety of intranasal oxytocin (OXT) to improve the quality of life and reduce chronic stress levels in the caregivers to the persons with dementia. Randomized, double-blind, placebo-controlled clinical trial of intranasal oxytocin (12 or 24 IU) will be conducted by daily administration (once a day) for 21 days (3 weeks).

开始日期2025-05-01

申办/合作机构

University of Nebraska

NCT06808516

/ Not yet recruiting临床2期

The OxyPLEASURE Study - Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency (Central Diabetes Insipidus) and Healthy Controls - a Double-blind Randomized Placebo-controlled Crossover Trial

The study aims to investigate whether intranasal oxytocin (OXT) improves sexual well-being in patients with Arginine Vasopressin Deficiency (AVP-D). The trial consists of two parts: Part A assesses the effect of OXT on sexual well-being and intimacy over a 7-day treatment period in participants in a stable partnership. Part B assesses the effect of a single dose OXT on sexual arousal, fear and empathy in a clinical setting and is designed for single participants and those in partnerships.

开始日期2025-04-01

申办/合作机构-

NCT06881459

/ Not yet recruitingN/AIIT

The Effect of Oxytocin on the Alpha Cell Response to Hypoglycaemia in Patients with Type 1 Diabetes

Investigating the effect of oxytocin on pancreatic endocrine functions by determining glucagon secretion during hypoglycemia in participants with type 1 diabetes.

开始日期2025-03-10

申办/合作机构-

100 项与缩宫素相关的临床结果

登录后查看更多信息

100 项与缩宫素相关的转化医学

登录后查看更多信息

100 项与缩宫素相关的专利（医药）

登录后查看更多信息

29,708

项与缩宫素相关的文献（医药）

2025-12-31·International Journal of Hyperthermia

Nomogram for predicting the efficacy of high-intensity focused ultrasound ablation for uterine fibroids based on oxytocin experimentation and ultrasonographic features: a retrospective single-center study

Article

作者: Chen, Mengqi ; Zhang, Danling ; Zou, Jianzhong ; Ding, Guisheng ; Chen, Sheng ; Wu, Songsong

OBJECTIVETo develop and validate a nomogram for predicting the effectiveness of high-intensity focused ultrasound (HIFU) ablation for uterine fibroids based on oxytocin experiments combined with sonographic features.METHODSSixty patients with uterine fibroids treated with HIFU combined with oxytocin for uterine fibroids were retrospectively analyzed. Before HIFU treatment, all patients underwent abdominal ultrasonography and oxytocin testing for classification. Predictive factors were selected through univariate and multivariate logistic regression analyses. A predictive model for the clinical efficacy of HIFU treatment of uterine fibroids was established using the R language. The model was visualized by a nomogram, and its discriminative ability, calibration, and clinical value were evaluated.RESULTSTypes of myomas, classification of blood flow around the myomas, location of the myomas, and classification of oxytocin were selected as the final predictive factors to construct the model. The calibration curve of the nomogram demonstrated good consistency between actual observations and nomogram predictions, with an absolute error of 0.066. The model's discriminative ability was evaluated by the area under the curve, which was 0.887 (95% CI: 0.818-0.955). The sensitivity and specificity were 84.4% and 78.8%, respectively, indicating that the model had a good predictive value for the ablation situation. Decision curve analysis showed that the model had high clinical applicability, with the maximum net benefit threshold probability interval ranging from 12.0% to 80.5%.CONCLUSIONThe prediction model for HIFU treatment of uterine fibroids, based on ultrasound characteristics and oxytocin test, shows strong predictive ability and may help clinicians choose suitable patients for treatment.

2025-04-01·Neuropsychopharmacology

Endocannabinoid contributions to the perception of socially relevant, affective touch in humans

Article

作者: Morrison, India ; Heilig, Markus ; Haggarty, Connor J ; Jones, Madeleine R ; Hill, Matthew N ; Petrie, Gavin N ; Lunge, Abigail R ; Mayo, Leah M

AbstractSocial relationships are central to well-being. A subgroup of afferent nerve fibers, C-tactile (CT) afferents, are primed to respond to affective, socially relevant touch and may mitigate the effects of stress. The endocannabinoid ligand anandamide (AEA) modulates both social reward and stress. We thus hypothesized that AEA levels would be associated with the perceived pleasantness of affective touch in humans. Across two studies, we explored perceptions of affective, socially relevant touch and general affective stimuli. In study 1, adult participants (N = 101) were recruited based on presence (CM+) or absence (CM−) of documented childhood maltreatment (N = 52 CM+; N = 49 CM−). In study 2, healthy individuals were randomized to receive an inhibitor of fatty acid amide hydrolase (FAAH; PF-04457845) to increase AEA levels (n = 16) or placebo (n = 29). Outcomes included self-report ratings of touch pleasantness and intensity, valence and arousal ratings of affective images, and plasma levels of endocannabinoids AEA and 2-AG, cortisol, and oxytocin. In study 1, higher AEA levels were associated with a reduced preference for affective, CT-optimal touch. In study 2, pharmacological elevation of AEA resulted in reduced preference for affective touch. These effects were specific to social processing, as AEA levels were not related to ratings of affective images. In contrast to our hypothesis, elevated AEA was associated with reduced pleasantness ratings of CT-optimal, affective touch. This provides novel, in-human data linking AEA to social processing, adding nuance to the rationale for its use as a potential novel therapeutic target in disordered in social processing.

2025-04-01·Psychoneuroendocrinology

Intranasal oxytocin increases breast milk oxytocin, but has a reduced effect in depressed mothers: A randomized controlled trial

Article

作者: Fearon, Pasco ; Hardiman, Paul ; Zagoory-Sharon, Orna ; Fonagy, Peter ; Lindley Baron-Cohen, Kate ; Meins, Elizabeth ; Feldman, Ruth

Oxytocin (OT) plays pivotal roles in stress regulation, mother-infant bonding, and breastfeeding, all of which are adversely impacted by postnatal depression (PND). In a double-blind, randomized controlled trial, we assessed endogenous OT concentrations first in the breast milk of new mothers at baseline, and second following the administration of exogenous OT compared to a placebo delivered via a nasal spray.METHODParticipants were mothers (N = 62, aged 23-42 years) and their infants (aged 3-9 months). Each mother underwent screening for PND symptoms using the Edinburgh Postnatal Depression Scale (EPDS). N = 26 mothers scored above the cut-off point (≥9) on the EPDS, and N = 36 mothers scored below. Breast milk samples, collected during breastfeeding, were assayed for OT content.RESULTSBaseline endogenous OT concentration in breast milk was not associated with maternal low mood. Exogenous OT administration was associated with a significant increase in breast milk OT, but with reduced effect in mothers experiencing symptoms of PND compared to control mothers.CONCLUSIONSFuture studies should test if breast milk OT exhibits a protective role against the developmental disadvantages of maternal PND on children. The current findings may reflect a possible disruption of the interaction between the central and peripheral OT pathways during breastfeeding in mothers experiencing symptoms of PND. These insights shed new light on the potential biological mechanisms involved in the transference of mental health vulnerabilities from mothers to infants.

310

项与缩宫素相关的新闻（医药）

2025-02-10

·GlobeNewswire-Health Care

Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.

The Acquired Portfolio of Infectious Disease Assets Includes a Class of Potential Broad Spectrum Oral Antiviral Agents, TNX-3900 with a Host-Directed Mechanism Tonix Plans to Develop the TNX-3900 Series of Molecules as Oral Antivirals Either as Monotherapy or in Combination with Other Antivirals The TNX-3900 Class of Antivirals Has a Novel Mechanism of Action Based on Inhibition of Certain Cathepsin Proteases which are Required for Cell Infection by Many Viruses like SARS-CoV-2 Sina Bavari, Ph.D., Tonix EVP of Infectious Disease R&D and Director of the Frederick, MD Research and Development Center (RDC) was a Scientific Founder of Healion Bio, Inc. Feb. 02, 2023 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has acquired all of the assets of Healion Bio, Inc. (Healion) including its entire portfolio of next-generation antiviral technology assets. Healion’s drug portfolio includes a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action. Host-directed antivirals modulate human cells and tissues and are different from direct-acting antivirals which inhibit virus proteins and processes. Tonix’s TNX-3900, formerly known as HB-121, are cathepsin protease inhibitors, some of which have strong activity in vitro against SARS-CoV-2. “We are excited to develop Healion’s drug programs that include TNX-3900, which is a class of drugs with potential broad spectrum anti-viral activity, either as monotherapies or in combination with other antivirals”, said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Broad-spectrum antiviral agents have the potential to reduce viral load and allow the adaptive immune system to alert the other arms of the immune system to mount a protective response. Examples of other classes of host-directed antivirals that have been approved by the U.S. Food and Drug Administration (FDA) include alpha interferon like Pegasys® (peginterferon alfa-2a) for viral hepatitis, the CCR5 antagonist Selzentry® (maraviroc) for HIV, and the anti-IL-6 receptor antagonist monoclonal antibody Actemra® (tocilizumab) for COVID-19.” Sina Bavari, Ph.D., Executive Vice President for Infectious Disease Research at Tonix said, “I am pleased to be reunited with the infectious disease assets of Healion, since I was the scientific founder of Healion after I retired from my position as Chief of R&D at the United States Army Medical Research Institute of Infectious Disease (USAMRIID). While Healion made some progress developing these advanced technologies, Tonix’s state-of-the art facilities and depth of drug development expertise have the potential to advance the TNX-3900 class of drugs into clinical trials. On behalf of the talented scientific team that I direct at our 48,000 square-foot cutting-edge infectious disease research facility in Frederick, Md., I am pleased to add this technology to the therapeutic development programs underway.” TNX-3900 is the term for a series of molecules that inhibit essential cathepsins which are required by viruses such as coronaviruses and filoviruses to infect cells. Because of the unique antiviral mechanism of these compounds, the Company believes they can potentiate the activity of other antivirals with differing mechanisms. The Company believes this makes cathepsin inhibitors suitable for combination therapy. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the second quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix initiated a Phase 2 study in Long COVID in the third quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the second quarter of 2023. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the first quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets) is a once-daily formulation of tianeptine being developed as a potential treatment for major depressive disorder (MDD) with a Phase 2 study expected to be initiated in the first quarter of 2023. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second quarter of 2023. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox, TNX-801, a next-generation vaccine to prevent COVID-19, TNX-1850, a platform to make fully human monoclonal antibodies to treat COVID-19, TNX-3600, and humanized anti-SARS-CoV-2 monoclonal antibodies, TNX-3800, recently licensed from Curia. TNX-801, Tonix’s vaccine in development to prevent smallpox and monkeypox, also serves as the live virus vaccine platform or recombinant pox vaccine (RPV) platform for other infectious diseases. A Phase 1 study of TNX-801 is expected to be initiated in Kenya in the second half of 2023. The content above comes from the network. if any infringement, please contact us to modify.

疫苗突破性疗法免疫疗法孤儿药

2025-01-20

·赛柏蓝

原研药：集采影响有多大？

特约作者 | 张自然博士责任编辑 | 郑瑶近日，原研药和集采引起广泛热议。集采对原研药影响有多大？原研药在集采中表现如何？ 01 涉及品种数以前5批及第10批国采为例，涉及原研药≥2个的有16家外企。其中，涉及原研药数量最多的是辉瑞、阿斯利康，分别涉及27个和20个原研药。辉瑞连续十多年雄踞外企在华销售榜首，近三年被阿斯利康取代冠军宝座，所以，国采涉及这两家的原研药数量最多也就不足为奇了；其次是默沙东、诺华、勃林格殷格翰、葛兰素、拜耳和赛诺菲等6家知名外企，国采涉及原研药都超过10个，分别有15个、14个、13个、13个、12个和10个；礼来、强生和施贵宝都涉及8个原研药；日本的武田、第一三共和中外制药分别涉及5个、4个和2个原研药。 02 中选品种数国采已进行了10批，除第10批外，每批都有原研药中选。前十批国采，共22家外企有原研药中选。其中，中选原研药数量最多的是赛诺菲，共中选了4个，如波立维（硫酸氢氯吡格雷片）、安博诺（厄贝沙坦氢氯噻嗪片）、索里昂（氨磺必利片）、注射用奥沙利铂。中选2个原研药的外企有6家，即拜耳、德国贝朗医疗、勃林格殷格翰、辉瑞、默沙东和通用电气药业。如拜耳的拜糖平（阿卡波糖）、贝朗的ω-3鱼油中/长链脂肪乳注射液、勃林格殷格翰的优尼（美洛昔康片）、辉瑞的斯沃（利奈唑胺片）、默沙东的顺尔宁（孟鲁司特钠片）以及通用电气的碘海醇注射液等。其他如阿斯利康、费森尤斯、葛兰素、施贵宝等15家外企都各中选了1个原研药。 03 降幅因原研药还要叠加专利悬崖效应，一般要以较大的降价幅度才能中选。但也不尽然，也有降幅很小就中选的。在前十批国采中选的原研药中，降价幅度最小的是丹麦利奥（LEO）的依安凡。降幅＜40%的有2个原研药，即丹麦利奥（LEO）的依安凡（阿法骨化醇软胶囊）、博莱科的典比乐（碘帕醇注射液），分别只降了30%、32%即一举中选；降幅40～60%的有6个原研药，即意大利ALFASIGMA S.p.A.的左卡尼汀注射液49%、德国贝朗医疗的中/长链脂肪乳注射液C8~24Ve50%和ω-3鱼油中/长链脂肪乳注射液60%、默沙东的顺尔宁（孟鲁司特钠）54%和瑞美隆（米氮平片）57%、葛兰素的安福达（度他雄胺软胶囊）55%、礼来的力比泰（培美曲塞）60%；降幅60～70%的有4个原研药，即通用电气的欧乃派克（碘海醇注射液）61%、费森尤斯卡比的敏新（脂肪乳氨基酸17葡萄糖）66%、施贵宝的蒙诺（福辛普利钠）69%、辉凌的巧特欣（卡贝缩宫素注射剂）70%。 END 内容沟通：郑瑶（13810174402）左下角「关注账号」，右下角「在看」，防止失联

带量采购核酸药物

2025-01-07

·GlobeNewswire-Health Care

Tonix Pharmaceuticals to Present at Two Upcoming January Investor Conferences

CHATHAM, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Tonix management will present and host investor meetings at the following January investor conferences: 8th Annual Neuroscience Innovation Forum by Sachs Associates Company PresentationPresenter:Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsDate:Sunday, January 12, 2025Place:Marines Memorial Club, San Francisco, Calif.Time:11:15 a.m. PTRoom:Track A – Room Rosenberg PanelParticipant:Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsTitle:Revolutionizing Neuropsychiatric Treatments: Novel Approaches PanelDate:Sunday, January 12, 2025Place:Marines Memorial Club, San Francisco, Calif.Time:1:15 p.m. PT 2025 Biotech ShowcasePresenter:Seth Lederman, M.D., President and Chief Executive Officer of Tonix PharmaceuticalsDate:Tuesday, January 14, 2025Place:Hilton San Francisco Union Square, San Francisco, Calif.Time:10:00 a.m. PTRoom:Yosemite C (Ballroom level) Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators. Replays of both webcasts of the Company’s presentations at the Neuroscience Innovation Forum and the 2025 Biotech Showcase will be available under the IR Events tab of the Tonix website at www.tonixpharma.com following each presentation. Tonix Pharmaceuticals Holding Corp.* Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing approval. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation, and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults. * Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners. This press release and further information about Tonix can be found at www.tonixpharma.com. Forward Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. Investor Contact Jessica MorrisTonix Pharmaceuticalsinvestor.relations@tonixpharma.com (862) 904-8182 Peter VozzoICR Healthcarepeter.vozzo@icrhealthcare.com (443) 213-0505 Media Contact Ray JordanPutnam Insightsray@putnaminsights.com(949) 245-5432

临床3期快速通道临床2期疫苗

100 项与缩宫素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00089	缩宫素	H01BB02	DB00107

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
宫缩乏力	澳大利亚	Viatris Pty Ltd.	1991-08-21
子宫出血	日本	ASKA Pharmaceutical Co., Ltd.	1984-07-12
流产	美国	Endo Operations Ltd.	1980-11-19
出血	美国	Endo Operations Ltd.	1980-11-19
催产	美国	Endo Operations Ltd.	1980-11-19
产后出血	美国	Endo Operations Ltd.	1980-11-19
人工流产	-	-	-

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
普拉德-威利综合症	临床2期	美国	Tonix Pharmaceuticals Holding Corp.	-
自闭症谱系障碍	药物发现	美国	The General Hospital Corp.	2017-10-09
心房中隔缺损	药物发现	美国	The General Hospital Corp.	2017-10-09
丛集性头痛	药物发现	智利	Trigemina, Inc.	2013-05-01
丛集性头痛	药物发现	新西兰	Trigemina, Inc.	2013-05-01
丛集性头痛	药物发现	澳大利亚	Trigemina, Inc.	2013-05-01
萎缩性阴道炎	药物发现	瑞典	Peptonic Medical AB	2010-08-01
萎缩性阴道炎	药物发现	英国	Peptonic Medical AB	2010-08-01
外阴和阴道萎缩	药物发现	瑞典	Peptonic Medical AB	2010-08-01
外阴和阴道萎缩	药物发现	英国	Peptonic Medical AB	2010-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05679908 (PREVENTION, CTgov)	临床2期	先兆偏头痛 \| 无先兆偏头痛	88	Placebo Nasal Spray (Placebo)	憲窪鏇願餘膚鏇網鹽繭(鏇積壓窪艱鬱齋構願選) = 醖壓憲願繭餘觸鹹鏇鹹製構網壓鏇艱襯醖憲遞 (淵廠醖襯製蓋餘鏇鏇廠, 選蓋憲糧廠夢壓夢鏇廠 ~ 獵憲築襯願構蓋醖鹽築) 更多	-	2025-02-25
				Placebo Nasal Spray+TNX-1900 (TNX-1900 Low Dose)	憲窪鏇願餘膚鏇網鹽繭(鏇積壓窪艱鬱齋構願選) = 觸顧夢鏇顧範鹽範範鏇製構網壓鏇艱襯醖憲遞 (淵廠醖襯製蓋餘鏇鏇廠, 衊憲衊範遞選獵選選簾 ~ 遞鹹窪衊艱鹽獵淵繭網) 更多
NCT02505984 (IN-OXT, CTgov)	临床2期	产后抑郁症 \| 焦虑症 \| 创伤后应激障碍	56	Oxytocin (Oxytocin)	淵簾餘糧鹹廠願淵獵蓋(簾餘簾遞膚艱鹹醖築餘) = 網廠襯願觸襯壓積繭齋襯鏇製窪積鹹範繭鑰獵 (膚餘餘顧鏇壓齋夢鹽鏇, 淵廠繭淵膚積廠衊壓鑰 ~ 選鹽艱獵糧製窪網壓遞) 更多	-	2025-02-25
				Placebo (Placebo)	淵簾餘糧鹹廠願淵獵蓋(簾餘簾遞膚艱鹹醖築餘) = 製鹽製鑰鬱憲鹽鬱蓋積襯鏇製窪積鹹範繭鑰獵 (膚餘餘顧鏇壓齋夢鹽鏇, 遞艱獵願鏇淵憲淵鹹襯 ~ 築願範糧觸窪範構餘鑰) 更多
NCT02737436 (OT-MOM, CTgov)	N/A	-	132	Placebo (Placebo)	積憲壓餘網壓鹹艱壓窪(膚憲淵鑰艱餘廠夢糧製) = 範範淵製遞獵糧繭願鬱範夢衊壓艱網齋夢蓋蓋 (獵膚積遞憲齋壓壓範蓋, 構製蓋夢網鏇壓獵膚夢 ~ 醖淵齋獵構壓艱餘選顧) 更多	-	2025-01-28
				Functional MRI scanning+Intranasal Oxytocin (Oxytocin)	積憲壓餘網壓鹹艱壓窪(膚憲淵鑰艱餘廠夢糧製) = 鹹齋窪願鬱艱膚繭壓鏇範夢衊壓艱網齋夢蓋蓋 (獵膚積遞憲齋壓壓範蓋, 壓淵鏇簾鹽繭膚壓膚遞 ~ 網齋鹽繭廠鬱網鏇鹹觸) 更多
NCT05672667 (CTgov)	临床1期	-	25	intravenous oxytocin	製夢夢壓製構鬱顧餘憲(廠襯鏇襯積顧觸廠築繭) = 積鏇鬱鹹廠選蓋繭鬱願鹽鏇壓憲餘齋糧製襯憲 (鏇鹽範窪襯築蓋願顧鏇, 鏇襯遞鹹壓壓範鬱構襯 ~ 網夢鑰顧餘衊廠獵製衊) 更多	-	2024-08-06
NCT03593473 (CTgov)	临床2期	产后抑郁症 \| 心理压力 \| 焦虑症	109	Intranasal Oxytocin (Intranasal Oxytocin)	齋淵鏇範壓範夢廠夢鏇(積壓顧構鏇餘壓壓窪構) = 齋衊襯築膚鏇糧夢餘艱繭繭鹽遞範膚鏇廠蓋願 (糧蓋餘顧蓋糧積襯憲夢, 襯廠簾憲窪製築淵製憲 ~ 鹹糧獵鬱積鹹淵遞鬱鹽) 更多	-	2024-05-24
				Placebo (Placebo)	齋淵鏇範壓範夢廠夢鏇(積壓顧構鏇餘壓壓窪構) = 憲繭網構繭膚衊襯積醖繭繭鹽遞範膚鏇廠蓋願 (糧蓋餘顧蓋糧積襯憲夢, 夢廠簾簾醖構膚願艱夢 ~ 廠築膚醖衊鏇繭範衊網) 更多
ChiCTR2300067953 (Pubmed \| Arch Gynecol Obstet)	N/A	-	360	Intravenous infusion of oxytocin	糧繭鏇觸遞網獵築憲窪(艱糧淵獵鏇觸衊遞夢淵) = 鬱齋鑰鹹蓋淵夢願醖獵艱鹽遞鹽獵顧網衊簾淵 (衊蓋築鏇憲齋醖壓淵網, 21.7)	不佳	2024-05-16
				Intramyometrial injection of oxytocin	糧繭鏇觸遞網獵築憲窪(艱糧淵獵鏇觸衊遞夢淵) = 觸壓鹹網憲製鑰鑰廠繭艱鹽遞鹽獵顧網衊簾淵 (衊蓋築鏇憲齋醖壓淵網, 24.3)
NCT04028765 (POM PROM, CTgov)	临床4期	胎膜早破	108	Misoprostol (Oral Misoprostol)	鏇鏇選憲網憲遞製繭鏇(糧蓋繭窪淵壓選壓鏇淵) = 築觸餘製淵築製窪糧艱窪鏇夢繭鹹壓夢鹹鹽衊 (膚窪遞淵觸鏇顧獵衊選, 網願獵廠鑰壓蓋鏇蓋艱 ~ 淵顧淵鹹遞鬱鏇構夢蓋) 更多	-	2024-04-30
				Oxytocin (Oxytocin)	鏇鏇選憲網憲遞製繭鏇(糧蓋繭窪淵壓選壓鏇淵) = 憲膚齋鹽範蓋獵築選願窪鏇夢繭鹹壓夢鹹鹽衊 (膚窪遞淵觸鏇顧獵衊選, 壓網窪築壓餘製製餘淵 ~ 蓋蓋醖醖窪構衊製夢壓) 更多
NCT02918864 (ION-ASD, CTgov)	临床2期	自闭症谱系障碍	40	Social Cognitive Skills Training+Oxytocin (ION-ASD)	範鏇憲膚淵鹹憲遞繭鏇(壓網顧範衊鏇衊膚窪衊) = 醖鬱鹹壓願醖築窪簾觸獵夢廠構觸淵衊憲鹽選 (鏇膚繭窪膚廠簾願願窪, 鹽憲鏇鏇鏇廠顧糧衊鹽 ~ 憲遞窪憲齋獵製蓋淵遞) 更多	-	2024-04-05
				Facilitated Play Therapy (Facilitated Play)	範鏇憲膚淵鹹憲遞繭鏇(壓網顧範衊鏇衊膚窪衊) = 艱獵淵選艱壓獵觸醖製獵夢廠構觸淵衊憲鹽選 (鏇膚繭窪膚廠簾願願窪, 願衊膚鹽網範餘網憲簾 ~ 顧鏇齋積積窪範窪艱鹹) 更多
NCT03043053 (Eight Weeks Intranasal Oxytocin vs. Placebo, CTgov)	临床2期	肥胖	61	oxytocin nasal spray (Oxytocin)	窪觸夢膚夢糧鹽餘築鑰(膚網遞構醖淵顧膚蓋膚) = 夢膚選構淵選觸鑰繭鹹觸鑰艱醖築壓鏇鑰齋築 (鹽膚艱遞遞鏇網蓋壓糧, 鹹壓膚鑰鹹顧簾鹽襯網 ~ 膚醖醖壓鹹蓋積顧鹽遞) 更多	-	2024-02-07
				Placebo (Placebo)	窪觸夢膚夢糧鹽餘築鑰(膚網遞構醖淵顧膚蓋膚) = 製構艱獵膚壓襯艱獵衊觸鑰艱醖築壓鏇鑰齋築 (鹽膚艱遞遞鏇網蓋壓糧, 艱簾獵淵願獵壓網範廠 ~ 築艱鏇網遞觸夢繭願願) 更多
NCT02205034 (OTBB2, CTgov)	临床1/2期	普拉德-威利综合症	18	oxytocin (First Arm)	鏇壓膚選艱齋獵壓積製(網衊築鹽網衊製鏇憲範) = 醖築窪窪繭範鏇願廠衊蓋遞繭繭齋構衊憲築衊 (鑰鹹壓膚獵窪構鏇觸襯, 醖鏇壓鏇簾蓋夢壓廠選 ~ 網淵淵網顧憲鏇餘範鑰) 更多	-	2023-12-04
				oxytocin (Second Arm)	鏇壓膚選艱齋獵壓積製(網衊築鹽網衊製鏇憲範) = 繭膚積衊鑰憲窪夢餘鏇蓋遞繭繭齋構衊憲築衊 (鑰鹹壓膚獵窪構鏇觸襯, 構製艱獵醖淵遞鏇餘願 ~ 艱鏇築鏇構衊艱齋鑰繭) 更多